Equities research analysts expect Agenus Inc (NASDAQ:AGEN) to post ($0.43) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Agenus’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.52). Agenus reported earnings of ($0.29) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 48.3%. The firm is scheduled to report its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Agenus will report full year earnings of ($1.04) per share for the current financial year, with EPS estimates ranging from ($1.12) to ($0.95). For the next financial year, analysts anticipate that the firm will report earnings of ($1.41) per share, with EPS estimates ranging from ($1.96) to ($0.98). Zacks’ EPS averages are an average based on a survey of research analysts that cover Agenus.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.05). The firm had revenue of $15.72 million for the quarter, compared to the consensus estimate of $5.37 million.
Separately, BidaskClub cut Agenus from a “sell” rating to a “strong sell” rating in a research note on Friday, July 26th.
Large investors have recently added to or reduced their stakes in the stock. Shell Asset Management Co. bought a new position in Agenus during the 1st quarter worth $197,000. Bank of New York Mellon Corp grew its position in Agenus by 26.6% in the fourth quarter. Bank of New York Mellon Corp now owns 442,886 shares of the biotechnology company’s stock worth $1,055,000 after acquiring an additional 92,957 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in Agenus in the fourth quarter worth $110,000. Geode Capital Management LLC grew its position in Agenus by 34.1% in the fourth quarter. Geode Capital Management LLC now owns 1,062,200 shares of the biotechnology company’s stock worth $2,528,000 after acquiring an additional 269,890 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its position in Agenus by 80,579.2% in the first quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 19,339 shares in the last quarter. Institutional investors and hedge funds own 34.31% of the company’s stock.
Shares of AGEN traded down $0.17 during trading hours on Friday, reaching $2.79. 777,062 shares of the company’s stock traded hands, compared to its average volume of 981,405. The firm has a market capitalization of $406.45 million, a price-to-earnings ratio of -1.94 and a beta of 1.86. Agenus has a twelve month low of $1.54 and a twelve month high of $3.88. The business’s fifty day simple moving average is $2.58 and its two-hundred day simple moving average is $2.81.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Read More: What is the Stochastic Momentum Index (SMI)?
Get a free copy of the Zacks research report on Agenus (AGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.